Entrada Therapeutics (TRDA) said Monday that the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.

The company said the 1b study is designed to evaluate ENTR-601-44's safety and tolerability in about 32 adults with DMD who are exon-44 skipping amenable.

Shares of Entrada Therapeutics were up more than 9% in recent premarket activity Monday.

Price: 14.28, Change: +1.24, Percent Change: +9.51